A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.

doi:10.1097/COC.0000000000001253

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.

American journal of clinical oncology - 1 Apr 2026

Álvarez-Gallego Rafael, Macarulla Teresa, Laquente Berta, Peinado Paloma, Castet Florian, Muñoz Cesar, Fabregat-Franco Carles, Ugidos Lisardo, Vega Sharela, Busquets Juli, Sanz-García Enrique, Toledano Carmen, Quijano Yolanda, Vicente Emilio, Cubillo Antonio

Abstract excerpt

OBJECTIVES: To evaluate the association between the KRAS mutational load and the histologic tumor response in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant treatment (NAC) with pegylated liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX). METHODS: This was a multicenter, single-arm, interventional, open-label, phase 2 trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Liquid Biopsy

Share to Neoadjuvant Therapy

Share to Oxaliplatin

Share to Pancreatic Neoplasms

Source

Open in PubMed

Identifiers

PMID: 40928497
DOI: 10.1097/COC.0000000000001253

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.PMID 40928497Read ↗

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.Semantic proximity Read ↗

Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.Semantic proximity Read ↗

Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.Semantic proximity Read ↗

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.Semantic proximity Read ↗

Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy.Semantic proximity Read ↗

New Therapeutic Targets in RAS Wild-type Pancreatic Cancer.Semantic proximity Read ↗

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.Semantic proximity Read ↗

Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data from the NORPACT-2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.